<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714412</url>
  </required_header>
  <id_info>
    <org_study_id>CL008</org_study_id>
    <nct_id>NCT03714412</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System</brief_title>
  <official_title>Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovalve Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovalve Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the safety and performance of the Cardiovalve transfemoral mitral valve&#xD;
      replacement system in treating patients with severe mitral regurgitation who are at high risk&#xD;
      for open chest surgery. The system is comprised of comprised of: 1) an Implant; 2) a Delivery&#xD;
      System (DS); and 3) Accessories that are required for the implantation procedure. the&#xD;
      procedure is performed under general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test the safety and performance of the Cardiovalve transfemoral mitral valve&#xD;
      replacement system in treating patients with severe mitral regurgitation who are at high risk&#xD;
      for open chest surgery. The system is comprised of comprised of: 1) an Implant; 2) a Delivery&#xD;
      System (DS); and 3) Accessories that are required for the implantation procedure. The implant&#xD;
      procedure is performed under general anesthesia, and the participants will be followed-up at&#xD;
      discharge, 1- 3-, 6-, 12- and 24-months post-procedure, in order to check the system&#xD;
      functionality and effect on their cardiology status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Amended and merged with AHEAD-EU study&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from major device- or procedure- related serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the safety of the Cardiovalve with its associated procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success of delivery and deployment of the device</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Technical success of delivery and deployment of the device in the correct position and retrieval of delivery catheter, without significant mitral stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from emergency surgery or reintervention</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from emergency surgery or reintervention related to the device or access procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from rehospitalizations or reinterventions due to the underlying condition</measure>
    <time_frame>30 days, 3 Months, 6 Months, 12 Months, and 24 Months</time_frame>
    <description>Freedom from rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, worsening of heart failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in MR grade</measure>
    <time_frame>30 days, 3-, 6-, 12 and 24-months</time_frame>
    <description>Reduction in MR grade to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR) Number of patients with reduction in MR grade from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>30 days, 3-, 6-, 12 and 24-months</time_frame>
    <description>Improvement from baseline in NYHA functional class; Number of patients with improvement in NYHA class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>30 days, 3-, 6-, 12 and 24-months</time_frame>
    <description>Increase in distance from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life from baseline</measure>
    <time_frame>30 days, 3-, 6-, 12 and 24-months</time_frame>
    <description>Improvement from baseline in quality-of-life (Kansas City Cardiomyopathy Questionnaire improvement by ≥ 10)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will undergo implantation with the Cardiovalve system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation</intervention_name>
    <description>Implantation of the Cardiovalve transfemoral mitral valve replacement system</description>
    <arm_group_label>Implantation</arm_group_label>
    <other_name>Cardiovalve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
        2. NYHA functional II, III or ambulatory IV 3. Severe mitral regurgitation (MR grade 3-4+)&#xD;
        with pronounced secondary MR etiology 4. Subject is on optimal guideline-directed medical&#xD;
        therapy for heart failure for at least 30 days or CRT if indicated.&#xD;
&#xD;
        5. Elevated risk for conventional open mitral valve repair or replacement surgery in the&#xD;
        consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and&#xD;
        imaging specialist as a minimum) based on STS/Euro Score II (per MVARC Part 1), frailty and&#xD;
        co-morbidities.&#xD;
&#xD;
        6. Able to undergo Transesophageal Echocardiography (TEE). 7. Subject understands the study&#xD;
        requirements and the treatment procedures and provides written Informed Consent before any&#xD;
        study-specific tests or procedures are performed.&#xD;
&#xD;
        8. The subject commits to return for the scheduled post-operative follow-up visits at the&#xD;
        hospital.&#xD;
&#xD;
        Anatomical Inclusion Criteria 9. Suitable for femoral access procedure and trans septal&#xD;
        catheterization 10. Native mitral valve geometry and size and LV outflow tract&#xD;
        characteristics compatible with the Cardiovalve (as assessed by the independent Screening&#xD;
        Committee)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cardiovascular Exclusion Criteria&#xD;
&#xD;
          1. Prior stroke or TIA within 3 months or Modified Rankin Scale ≥4 disability&#xD;
&#xD;
          2. Acute myocardial infarction within the previous 30 days&#xD;
&#xD;
          3. Any prior heart valve surgery or transcatheter mitral intervention&#xD;
&#xD;
          4. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid&#xD;
             surgery within 30 days&#xD;
&#xD;
          5. Rheumatic heart disease or endocarditis within the previous 3 months&#xD;
&#xD;
          6. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology&#xD;
&#xD;
          7. Existence of inferior vena cava filter or atrial septal device (contraindicating&#xD;
             femoral access and transseptal catheterization)&#xD;
&#xD;
          8. Untreated clinically signiﬁcant coronary artery disease requiring revascularization&#xD;
&#xD;
          9. Tricuspid valve disease requiring surgery or severe tricuspid regurgitation&#xD;
&#xD;
         10. Aortic or pulmonic valve disease requiring surgery&#xD;
&#xD;
         11. CRT/ICD implant within 30 days Anatomical Exclusion Criteria (assessed by&#xD;
             pre-procedural imaging)&#xD;
&#xD;
         12. Left Ventricular Ejection Fraction (LVEF) &lt;30%&#xD;
&#xD;
         13. LV end diastolic diameter &gt; 70mm&#xD;
&#xD;
         14. Significant abnormalities of the mitral valve and sub-valvular apparatus.&#xD;
&#xD;
         15. Severe mitral annular or leaflets calcification&#xD;
&#xD;
         16. Left atrial or LV thrombus or vegetation&#xD;
&#xD;
         17. Severe right ventricular dysfunction&#xD;
&#xD;
         18. Severe tricuspid or aortic valve disease&#xD;
&#xD;
             General Exclusion Criteria&#xD;
&#xD;
         19. Subject who is currently participating in an investigational study, other than this&#xD;
             study&#xD;
&#xD;
         20. Hemodynamic instability defined as systolic pressure &lt; 90mmHg or the need for&#xD;
             inotropic support or intra-aortic balloon pump or other hemodynamic support device, or&#xD;
             any mechanical heart assistance&#xD;
&#xD;
         21. Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated,&#xD;
             has an allergy to Nitinol alloys (nickel and titanium), or has intolerance to&#xD;
             antiplatelet, anticoagulant, or thrombolytic medications&#xD;
&#xD;
         22. Bleeding diathesis or hypercoagulable state&#xD;
&#xD;
         23. Active peptic ulcer or active gastrointestinal bleeding&#xD;
&#xD;
         24. Pulmonary artery systolic pressure &gt;70 mmHg&#xD;
&#xD;
         25. Patients with renal insufficiency (creatinine &gt; 2.5 mg/dL)&#xD;
&#xD;
         26. Need for emergent or urgent surgery for any reason or any planned cardiac Surgery&#xD;
             within the next 12 months&#xD;
&#xD;
         27. Subject with hepatic insufficiency&#xD;
&#xD;
         28. Subject has a co-morbid illness that may result in a life expectancy of less than one&#xD;
             year&#xD;
&#xD;
         29. Active infection that requires antibiotic therapy&#xD;
&#xD;
         30. Subject is pregnant, breastfeeding or intend to become pregnant within one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hygeia Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

